-+ 0.00%
-+ 0.00%
-+ 0.00%

REPLIMUNE SHARES DOWN 25% PREMARKET AFTER FDA STAFF FLAGS EFFICACY CONCERNS ON CO'S SKIN CANCER THERAPY

Reuters·07/28/2026 11:40:13

Please log in to view news